|
|
|
Stem Cell Related Patent Number US6866843
| Title: | Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell | | Inventors: | Habener, Joel F.; Newton Centre, MA, USA | | Summary: | Described herein is a method of treating diabetes mellitus or liver disease via the transfer of a nestin-positive pancreatic stem cell into a patient following the isolation of the stem cell from a pancreatic islet of a donor. The invention encompasses methods and compositions for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. The authors describe nestin as having been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are included whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Also provided are methods for the ex vivo differentiation of the pancreatic stem cells, and for their isolation, expansion and transplantation into a patient in need of such therapy, whether allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting or other cells. Further therapeutic applications include stem cell mobilization, myeloprotection, neuronal protection, wound healing, the treatment of cancer and parasitic infections, and the regulation of hematopoiesis. | | Abstract: | Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6866843 | | Application Number: | US2000000731255 | | Date Filed: | 06/12/2002 | | Date Published: | 15/03/2005 | | Assignee: | Viacell, Inc., Charlestown, MA, USA |
|
|
